Successful Retransplantation With Killer Cell Immunoglobulin-like Receptor Ligand-mismatched Cord Blood in Infant Acute Lymphoblastic Leukemia That Relapsed After Transplantation. Issue 4 (9th May 2023)

• Record Type: Journal Article
• Authors: Mizuki, Kazuyoshi; Honda, Yuko; Asai, Hiroshi; Higuchi, Naoko; Morita, Hiromi; Yabe, Hiromasa; Kusuhara, Koichi
• Is Part Of: Journal of pediatric hematology/oncology. Volume 45:Issue 4(2023)
• Page Start: e547
• Page End: e550
• Publication Date: 2023-05-09
• Subjects: infant B-cell precursor acute lymphoblastic leukemia -- KMT2A -- killer inhibitory receptors -- reduced-intensity conditioning -- central nervous system relapse; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002614
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : The prognosis of children with KMT2A -rearranged ( KMT2A -r) acute lymphoblastic leukemia (ALL) remains dismal. This report describes the successful retransplantation of a patient with infant ALL who relapsed both bone marrow and central nervous system. The patient received HLA-matched cord blood transplantation (CBT) and relapsed 18 months later. After achieving the second remission, the patient received a killer cell immunoglobulin-like receptor ligand-mismatched CBT with a reduced-intensity conditioning regimen and has been in remission for 52 months. Thus, killer cell immunoglobulin-like receptor ligand-mismatched CBT with reduced-intensity conditioning might be a treatment option for patients with KMT2A- r ALL who relapsed after transplantation, even with extramedullary relapse.